Welcome to our dedicated page for LBPS news (Ticker: LBPS), a resource for investors and traders seeking the latest updates and insights on LBPS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LBPS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LBPS's position in the market.
4D pharma plc (NASDAQ: LBPS) will hold a virtual Key Opinion Leader (KOL) event on January 27, 2022, at 8:00 a.m. ET to discuss positive topline results from its Phase I/II trial of MRx-4DP0004 for asthma treatment. The event will feature presentations from management and Professor Chris Brightling from the University of Leicester. The webcast will be accessible on the 4D pharma website, and a replay will be available post-event.
4D pharma focuses on Live Biotherapeutic products (LBPs) derived from the microbiome, with several ongoing clinical programs.
4D pharma plc (NASDAQ: LBPS), a leader in Live Biotherapeutic products, announced that CEO Duncan Peyton and CSO Alex Stevenson will present at the H.C. Wainwright BioConnect Conference, available for on-demand viewing from January 10, 2022, at 7:00 a.m. ET. The presentation will be accessible for 90 days on the company’s website. 4D pharma specializes in developing drugs derived from the microbiome, with six clinical studies underway, including treatments for Irritable Bowel Syndrome and pancreatic cancer, and collaborations with Merck & Co. for vaccine development.
4D pharma plc announces the appointment of John Doyle as its new Chief Financial Officer (CFO). Mr. Doyle, with over 15 years of experience in financial operations and investor relations within public healthcare companies, aims to drive the company's financial strategy as it continues to advance its Live Biotherapeutic programs. CEO Duncan Peyton expressed enthusiasm about Doyle's expertise, particularly following the company's NASDAQ listing in 2021. 4D pharma is focused on developing innovative drugs derived from the microbiome to address unmet medical needs.
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) has announced positive topline results from Part A of a Phase I/II clinical trial for MRx-4DP0004, an oral Live Biotherapeutic product aimed at asthma treatment.
Part A met its primary endpoint of safety and tolerability, showing no serious adverse events. Additionally, key secondary endpoints indicated improved asthma control, including reduced dependency on rescue medication and enhanced quality of life scores. The company plans to advance to Part B of the trial with up to 90 participants.
4D pharma plc, a leader in Live Biotherapeutics, announced new findings from the Phase II trial of Blautix® for irritable bowel syndrome (IBS-C and IBS-D). The trial included 353 patients, showing significant gut microbiome changes post-treatment, with Blautix outperforming placebo. These findings highlight Blautix's potential as a novel treatment option for IBS, addressing unmet medical needs worldwide. The company awaits FDA feedback regarding further development strategies for Blautix amidst ongoing review delays due to COVID-19.
4D pharma plc (NASDAQ: LBPS) announces management participation in the Jefferies London Virtual Healthcare Conference on November 18-19, 2021. The company is a leader in developing Live Biotherapeutics, biological products derived from the microbiome, and is recognized for its proprietary platform, MicroRx®. Currently, it has five clinical programs, including a Phase I/II study of MRx0518 combined with KEYTRUDA for solid tumors and a completed Phase II trial of Blautix® for IBS. Additionally, 4D pharma collaborates with MSD for vaccine development.
4D pharma plc (NASDAQ: LBPS), a leader in Live Biotherapeutic product development, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021. The webcast will be accessible on their website starting at 8:00 a.m. ET (1:00 p.m. BST). 4D pharma specializes in drugs derived from the microbiome, utilizing their proprietary MicroRx® platform. The company has five clinical programs, including collaborations with MSD for vaccine-related LBPs. Further details can be found at www.4dpharmaplc.com.
4D pharma (NASDAQ: LBPS) presented new biomarker analyses of its lead product, MRx0518, at the ESMO Congress from September 16-21, 2021, indicating its potential to enhance cancer treatment. One presentation revealed baseline biomarkers predicting clinical benefits from MRx0518, while the other demonstrated significant gene signature changes suggesting immune activation in patients. Data from ongoing trials could help identify patients most likely to respond to MRx0518 therapy, advancing its development toward regulatory approval.
4D pharma (NASDAQ: LBPS) announced its participation in two virtual investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 07:00 ET and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 08:15 ET. Webcasts of these events will be available on the company’s website for 90 days post-event. 4D pharma is a leader in developing Live Biotherapeutics targeting various diseases, backed by proprietary technology and multiple clinical programs.
4D pharma plc (NASDAQ: LBPS) announces two poster presentations at the ESMO Congress from September 16-21, 2021. The presentations will focus on "Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors" and "Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumors." MRx0518, a Live Biotherapeutic product, is being evaluated in three clinical trials, including combinations with KEYTRUDA and preoperative radiotherapy for pancreatic cancer.
